ArticleJournal of virological methods2010
The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.
Article in Journal of virological methods, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- A Highly Specific Antibody-Based Assay forViruses · 2025Article
- Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus.Viruses · 2023Article
- MxB Disrupts Hepatitis C Virus NS5A-CypA Complex: Insights From a Combined Theoretical and Experimental Approach.Frontiers in microbiology · 2022Article
- Development of a rapid homogeneous immunoassay for detection of rotavirus in stool samples.Frontiers in public health · 2022Article
- Induction of DUSP14 ubiquitination by PRMT5-mediated arginine methylation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- A Homogeneous Time-Resolved Fluorescence Immunoassay Method for the Measurement of Compound W.Biomarker insights · 2018Article
- Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs.Scientific reports · 2017Article
- Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit.Scientific reports · 2017Article
- Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA.Frontiers in immunology · 2017Article
- Review
- Chaperones in hepatitis C virus infection.World journal of hepatology · 2016Review
- Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Current opinion in virology · 2014Review
- Host-targeting agents in the treatment of hepatitis C: a beginning and an end?Antiviral research · 2013Review
- Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2013Review
- Article
- HCV NS5A and IRF9 compete for CypA binding.Journal of hepatology · 2013Article
- Profile of alisporivir and its potential in the treatment of hepatitis C.Drug design, development and therapy · 2013Review
- Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection.Viruses · 2012Review
- Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.Antimicrobial agents and chemotherapy · 2012Article
- Correlation between NS5A dimerization and hepatitis C virus replication.The Journal of biological chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cyclosporine A (CsA) is an immunosuppressive molecule that also impedes replication of hepatitis C virus (HCV). CsA inhibits isomerase activity of cellular-encoded cyclophilin proteins, of which cyclophilin A (CypA) in particular is required for HCV replication. Evidence suggests that the HCV-encoded NS5A and NS5B proteins may govern dependence of the virus on CypA-mediated isomerase activity, although the molecular mechanisms involved are unclear. However, association of NS5A and NS5B, with CypA has been reported, raising the possibility that direct interaction between these proteins facilitates HCV replication. In the present study, mammalian two-hybrid and AlphaLISA technologies were utilized to detect interactions between NS5A and NS5B, with CypA. AlphaLISA analysis revealed associations between NS5A and CypA using purified proteins, and in cell lysates prepared from co-transfected cells. Importantly, the NS5A-CypA interactions were sensitive to CsA in a dose-responsive manner and an isomerase mutant of CypA interacted with NS5A less efficiently than wild-type CypA. These findings correlate the anti-HCV properties of CsA with an ability of the compound to disrupt NS5A-CypA interactions in vitro and in vivo, whilst providing the basis for development of assay platforms suitable to screen compound libraries for novel inhibitors of the NS5A-CypA interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.